Jongen-Lavrencic M - Search Results

1

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.

Löwenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, Ferrant A, Sonneveld P, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, Breems D, de Muijnck H, Schaafsma R, Verhoef G, Döhner H, Gratwohl A, Pabst T, Ossenkoppele GJ, Maertens J; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German Austrian AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). Löwenberg B, et al. Blood. 2010 Apr 1;115(13):2586-91. doi: 10.1182/blood-2009-10-246470. Epub 2010 Jan 26. Blood. 2010. PMID: 20103782 Free article. Clinical Trial.

2

Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.

Barragán E, Montesinos P, Camos M, González M, Calasanz MJ, Román-Gómez J, Gómez-Casares MT, Ayala R, López J, Fuster Ó, Colomer D, Chillón C, Larrayoz MJ, Sánchez-Godoy P, González-Campos J, Manso F, Amador ML, Vellenga E, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups. Barragán E, et al. Haematologica. 2011 Oct;96(10):1470-7. doi: 10.3324/haematol.2011.044933. Epub 2011 Jun 17. Haematologica. 2011. PMID: 21685470 Free PMC article.

3

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.

Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ, Huijgens PC, Maertens J, Gratwohl A, Schaafsma R, Schanz U, Graux C, Schouten HC, Ferrant A, Bargetzi M, Fey MF, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). Vellenga E, et al. Blood. 2011 Dec 1;118(23):6037-42. doi: 10.1182/blood-2011-07-370247. Epub 2011 Sep 27. Blood. 2011. PMID: 21951683 Free article. Clinical Trial.

4

The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML.

Sun SM, Rockova V, Bullinger L, Dijkstra MK, Döhner H, Löwenberg B, Jongen-Lavrencic M. Sun SM, et al. Leukemia. 2013 Jan;27(1):100-6. doi: 10.1038/leu.2012.158. Epub 2012 Jun 13. Leukemia. 2013. PMID: 22692398

5

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years.

Cornelissen JJ, Versluis J, Passweg JR, van Putten WL, Manz MG, Maertens J, Beverloo HB, Valk PJ, van Marwijk Kooy M, Wijermans PW, Schaafsma MR, Biemond BJ, Vekemans MC, Breems DA, Verdonck LF, Fey MF, Jongen-Lavrencic M, Janssen JJ, Huls G, Kuball J, Pabst T, Graux C, Schouten HC, Gratwohl A, Vellenga E, Ossenkoppele G, Löwenberg B; HOVON; SAKK Leukemia Groups. Cornelissen JJ, et al. Leukemia. 2015 May;29(5):1041-50. doi: 10.1038/leu.2014.332. Epub 2014 Nov 27. Leukemia. 2015. PMID: 25428261

6

Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG.

Nowek K, Sun SM, Bullinger L, Bindels EM, Exalto C, Dijkstra MK, van Lom K, Döhner H, Erkeland SJ, Löwenberg B, Jongen-Lavrencic M. Nowek K, et al. Leukemia. 2016 Jan;30(1):229-37. doi: 10.1038/leu.2015.183. Epub 2015 Jul 15. Leukemia. 2016. PMID: 26174629

7

Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.

Dinmohamed AG, Visser O, van Norden Y, Blijlevens NM, Cornelissen JJ, Huls GA, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Ossenkoppele GJ, Löwenberg B, Jongen-Lavrencic M. Dinmohamed AG, et al. Leukemia. 2016 Jan;30(1):24-31. doi: 10.1038/leu.2015.188. Epub 2015 Jul 17. Leukemia. 2016. PMID: 26183645

8

Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival.

Dinmohamed AG, Szabó A, van der Mark M, Visser O, Sonneveld P, Cornelissen JJ, Jongen-Lavrencic M, Rijneveld AW. Dinmohamed AG, et al. Leukemia. 2016 Feb;30(2):310-7. doi: 10.1038/leu.2015.230. Epub 2015 Aug 19. Leukemia. 2016. PMID: 26286115

9

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry.

Dinmohamed AG, van Norden Y, Visser O, Posthuma EF, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M. Dinmohamed AG, et al. Leukemia. 2015 Dec;29(12):2449-51. doi: 10.1038/leu.2015.220. Epub 2015 Sep 15. Leukemia. 2015. PMID: 26369829 No abstract available.

10

Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age.

Nowek K, Sun SM, Dijkstra MK, Bullinger L, Döhner H, Erkeland SJ, Löwenberg B, Jongen-Lavrencic M. Nowek K, et al. Leukemia. 2016 Feb;30(2):303-9. doi: 10.1038/leu.2015.282. Epub 2015 Oct 14. Leukemia. 2016. PMID: 26464168

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75 results

Search Page

Filters